Xoma | XOMA - Selling And Administration Expenses


Xoma reported $11M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Agenus USD 10.56M 13.04M Dec/2025
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Ardelyx USD 102.27M 26.35M Mar/2026
aTyr Pharma USD 700.63K 81.56M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Celldex Therapeutics USD 11.45M 3.61M Mar/2026
Curis USD 1.34M 3.45M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Incyte USD 328.1M 62.31M Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Prothena USD 12.67M 5.02M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Xoma USD 11M 2.54M Jun/2024